Robert Discordia, PhD
Co-Founder, President & Chief Executive Officer Equulus Thrapeutics
Dr. Robert Discordia is Co-Founder, President & CEO of EQUULUS Therapeutics, a biotechnology company focused on developing next-generation therapies for central nervous system disorders, including addiction depression and PTSD. He has over three decades of experience in the pharmaceutical and biotechnology industry.
Seminars
10.00 – EQL-988: Expanding Rapid Treatment for Suicidality Beyond Ketamine by EQUULUS Therapeutics
10.15 – Building a Best-in-class Cell Therapy for Parkinson’s Disease by Treefrog Therapeutics
10.30 – First-In-Class Inhibitors of ALOX15 for Agitation in Dementia and Pain by Kinoxis Therapeutics
10.45 – A First-in-Class Intranasal Nanobody for Treatment-Resistant Depression by EvoDenovo
11.00 – Olfactory Neurons as a Longitudinal, Molecular Window into Patient Brain Biology by Crownlands
11.15 – MB-204: A Novel A2a Receptor Antagonist to the Restore Social Reward Signal in Autism, Depression & Alzheimer’s Disease by Marvel Biotechnology
11.30 – Presentation by Beacon Neuroscience
